Canada Spends Logo

Explore our Budget 2026 analysis

Program directory · National Research Council Canada

Biologics Manufacturing Centre

Program code
BNQ26 (NRC)
Core responsibility
Science and Innovation
In Departmental Plans
2023-24 – 2026-27 · New since an earlier plan

What it does

The Biologics Manufacturing Centre (BMC) is an end-to-end Good Manufacturing Practices (GMP) biomanufacturing facility located at the NRC Royalmount campus. The BMC is self-contained and is managed and operated by a not-for-profit (NFP) entity to fulfill its public good mandate. The NRC leases the facility to this organization and provides $17 million per year through a contribution agreement to offset facility operational costs. While the BMC outputs and outcomes are not directly under control of the NRC, its performance is monitored to ensure effective stewardship of Government funds.

The BMC was built by the NRC to provide Canada with a domestic vaccine production capacity, and the ability to produce, especially in times of need in the supply chain. In non-pandemic periods, the BMC provides domestic capacity to undertake public interest projects, such as the production of orphan drugs for rare diseases, to support improved health outcomes for Canadians and protect those at high risk. The BMC may also provide domestic biomanufacturing GMP production for universities and SMEs, to contribute to the sector’s growth, knowledge and capacity.

Given the NFP arrangement that is being put in place, the long-term role of the NRC will be to provide effective oversight of the contribution agreement between the BMC and the NRC and to see that the objectives of the BMC are being realized.

Source: the department's Program Inventory, via GC InfoBase.

History and lineage

First appears in GC InfoBase's actual spending by program in 2023-24. The data does not record when a program was created; it may be older than its first appearance here, which is limited by the sources (program spending starts in 2010-11, Departmental Plans in 2018-19).

2023-242024-252025-262026-272027-282028-29Biologics Manufacturing Centre 2023-24: $21.2MBiologics Manufacturing Centre 2024-25: $27.3MBiologics Manufacturing Centre 2025-26: $38.2MBiologics Manufacturing Centre 2026-27: $21MBiologics Manufacturing Centre 2027-28: $21MBiologics Manufacturing Centre 2028-29: $18.7MBiologics Manufacturing Centre
Bars: spending by fiscal year (dark: actual; light: actual restated on the 2017-18 program structure; outlined: the latest plan's forecast; grey: related programs). Bands: each program in the lineage over the years it has data.
ProgramRelationYears with dataActual spending over those years
Biologics Manufacturing CentreThis program2023-24 – 2028-29$48.5M

No earlier or later program in the same department has a similar name.

Significant changes in scope and budget

Detected from the data: renames between plans, programs it appears to replace, merge with or split into (matched by name), year-over-year changes in spending of at least 25% and $5M, or in employees of at least 20% and 25 FTEs, linked budget measures, and results indicators added or dropped.

YearWhat changedSource
2024-25Spending $27.3M, against $21.2M in 2023-24 (+29%).Actual spending (GC InfoBase)
2025-26Indicators added: Percentage of time that the BMC facility is operationalDepartmental Results Framework (GC InfoBase)
2025-26Indicators dropped: Composite score of BMC objectives and obligations met by the not-for-profitDepartmental Results Framework (GC InfoBase)
2025-26Planned spending $38.2M, against $27.3M in 2024-25 (+40%).Latest Departmental Plan
2026-27Planned spending $21M, against $38.2M in 2025-26 (−45%).Latest Departmental Plan

Success criteria

The program's indicators from its department's Departmental Results Framework: the target set in each year's plan, and the result reported the following year. Source: GC InfoBase.

Historical: targets against results

Composite score of BMC objectives and obligations met by the not-for-profit
Expected result: Effective stewardship of NRC’s financial contribution to the not-for-profit for governance of BMC operations
97.5%2023-24✓ met86%2024-25✓ met

Bars: result reported. Dashed line: target.

Report yearTargetDueResultStatus
2023-24≥ 80%202497.5%Met
2024-25≥ 80%202586%Met

Current: the 2026-27 plan's targets

Percentage of time that the BMC facility is operational
Expected result: A domestic, Good Manufacturing Practices (GMP)-compliant biomanufacturing facility is available to Canadian firms and to respond to pandemics and other health emergencies
97%2026-27

Bars: result reported. Dashed line: target.

Report yearTargetDueResultStatus
2026-27≥ 97%2027—Planned

Future goals: targets due after 2026-27

No targets with a later due date.

Spending and employees: planned against actual

Spending

2023-24: $19.6M2023-24: $21.2M2023-242024-25: $20M2024-25: $27.3M2024-252025-26: $38.2M2025-262026-27: $21M2026-272027-28: $21M2027-282028-29: $18.7M2028-29
Outlined bar: planned in that year's Departmental Plan (dashed: the latest plan, for years not yet reported). Filled bar: actual.
Show the numbers
Fiscal yearPlannedActual
2023-24$19.6M$21.2M
2024-25$20M$27.3M
2025-26$38.2M—
2026-27$21M—
2027-28$21M*—
2028-29$18.7M*—

Employees (FTEs)

2023-24: 02023-24: 02023-242024-25: 02024-25: 02024-252025-26: 02025-262026-27: 02026-272027-28: 02027-282028-29: 02028-29
Outlined bar: planned in that year's Departmental Plan (dashed: the latest plan, for years not yet reported). Filled bar: actual.
Show the numbers
Fiscal yearPlannedActual
2023-2400
2024-2500
2025-260—
2026-270—
2027-280*—
2028-290*—

Planned spending, plan by plan

Each row is one year's Departmental Plan and its forecast for the next three fiscal years; read a column down to see how the forecast for one year changed. The last row is what was actually spent. Click an amount for its source. Biggest changes in federal spending plans

Actual spending is from Departmental Results Reports and the Public Accounts, as published in GC InfoBase. FTEs are full-time equivalents.